Research programme: cancer therapeutics - L.E.A.F. Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - L.E.A.F. Pharmaceuticals

Alternative Names: LEAF-1401; LEAF-1401-1601; LEAF-1402; LEAF-1402-1602; LEAF-1403; LEAF-1404; LEAF-5816

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator L.E.A.F. Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Aug 2017 L.E.A.F. Pharmaceuticals has patents pending related to its intellectual property
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top